FDA is­sues sec­ond CRL to Su­per­nus for Parkin­son's drug-de­vice com­bo

It seems Su­per­nus Phar­ma­ceu­ti­cals will need a su­per ef­fort to get its Parkin­son’s treat­ment ap­proved.

The FDA re­ject­ed the com­pa­ny’s ther­a­py for a sec­ond time in 18 months, with Su­per­nus say­ing in a news re­lease on Mon­day that the reg­u­la­tor doesn’t think the ap­pli­ca­tion for SPN-830 is “ready for ap­proval in its cur­rent form.”

Su­per­nus shares $SUPN were down 10% pre­mar­ket but re­bound­ed slight­ly, trad­ing down about 4% af­ter the mar­ket opened on Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER